SG11201810210UA - Engineered botulinum neurotoxins - Google Patents
Engineered botulinum neurotoxinsInfo
- Publication number
- SG11201810210UA SG11201810210UA SG11201810210UA SG11201810210UA SG11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- boston
- pct
- disclosed
- substitution mutations
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 4
- 231100001103 botulinum neurotoxin Toxicity 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 241001112695 Clostridiales Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347579P | 2016-06-08 | 2016-06-08 | |
| PCT/US2017/036628 WO2017214447A1 (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810210UA true SG11201810210UA (en) | 2018-12-28 |
Family
ID=59227906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810210UA SG11201810210UA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
| SG10201912099TA SG10201912099TA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912099TA SG10201912099TA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11104891B2 (https=) |
| EP (1) | EP3468985A1 (https=) |
| JP (2) | JP7152392B2 (https=) |
| KR (1) | KR20190025906A (https=) |
| CN (1) | CN109476713A (https=) |
| AU (1) | AU2017277905B2 (https=) |
| BR (1) | BR112018075363A2 (https=) |
| CA (1) | CA3026492A1 (https=) |
| EA (1) | EA201892784A1 (https=) |
| IL (1) | IL263058B2 (https=) |
| MX (1) | MX2018015254A (https=) |
| SG (2) | SG11201810210UA (https=) |
| WO (1) | WO2017214447A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| US11242515B2 (en) * | 2016-05-16 | 2022-02-08 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US12098169B2 (en) | 2017-09-29 | 2024-09-24 | Children's Medical Center Corporation | Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
| KR20230001254A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| KR20230001260A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| WO2023068485A1 (ko) * | 2021-10-22 | 2023-04-27 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물 |
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| CN114410683B (zh) * | 2022-01-12 | 2023-11-28 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的RIM3-RNAi及其应用 |
| CN114369623B (zh) * | 2022-01-12 | 2023-07-07 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用 |
| GB202206348D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
| WO2025065012A1 (en) * | 2023-09-21 | 2025-03-27 | The Medical College Of Wisconsin, Inc. | Botulinum neurotoxin variants, constructs, compositions, and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| EP2366787B1 (en) * | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| US8273865B2 (en) | 2006-03-15 | 2012-09-25 | Allergan, Inc. | Multivalent clostridial toxins |
| SG10201606666XA (en) * | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| EP3270951B1 (en) * | 2015-03-16 | 2020-09-09 | California Institute of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2017
- 2017-06-08 CN CN201780035648.4A patent/CN109476713A/zh active Pending
- 2017-06-08 IL IL263058A patent/IL263058B2/en unknown
- 2017-06-08 KR KR1020197000585A patent/KR20190025906A/ko not_active Ceased
- 2017-06-08 JP JP2019516917A patent/JP7152392B2/ja active Active
- 2017-06-08 SG SG11201810210UA patent/SG11201810210UA/en unknown
- 2017-06-08 EA EA201892784A patent/EA201892784A1/ru unknown
- 2017-06-08 BR BR112018075363-7A patent/BR112018075363A2/pt not_active IP Right Cessation
- 2017-06-08 EP EP17733667.4A patent/EP3468985A1/en not_active Withdrawn
- 2017-06-08 SG SG10201912099TA patent/SG10201912099TA/en unknown
- 2017-06-08 AU AU2017277905A patent/AU2017277905B2/en not_active Ceased
- 2017-06-08 WO PCT/US2017/036628 patent/WO2017214447A1/en not_active Ceased
- 2017-06-08 US US16/308,146 patent/US11104891B2/en active Active
- 2017-06-08 CA CA3026492A patent/CA3026492A1/en active Pending
- 2017-06-08 MX MX2018015254A patent/MX2018015254A/es unknown
-
2022
- 2022-03-18 JP JP2022044568A patent/JP2022112031A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017277905B2 (en) | 2022-04-14 |
| MX2018015254A (es) | 2019-08-16 |
| KR20190025906A (ko) | 2019-03-12 |
| IL263058B1 (en) | 2023-07-01 |
| AU2017277905A1 (en) | 2018-12-20 |
| CN109476713A (zh) | 2019-03-15 |
| WO2017214447A1 (en) | 2017-12-14 |
| BR112018075363A2 (pt) | 2019-03-19 |
| JP7152392B2 (ja) | 2022-10-12 |
| SG10201912099TA (en) | 2020-02-27 |
| IL263058B2 (en) | 2023-11-01 |
| JP2022112031A (ja) | 2022-08-01 |
| US11104891B2 (en) | 2021-08-31 |
| IL263058A (en) | 2018-12-31 |
| JP2019523015A (ja) | 2019-08-22 |
| EP3468985A1 (en) | 2019-04-17 |
| CA3026492A1 (en) | 2017-12-14 |
| EA201892784A1 (ru) | 2019-05-31 |
| US20190300869A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810210UA (en) | Engineered botulinum neurotoxins | |
| SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201903089RA (en) | Aav delivery of nucleobase editors | |
| SG11201901941YA (en) | High purity rna compositions and methods for preparation thereof | |
| SG11201407784UA (en) | Engineered botulinum neurotoxin | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11201908393YA (en) | Modulators of pcsk9 expression |